ID: ALA342478

Max Phase: Preclinical

Molecular Formula: C11H8N2O5

Molecular Weight: 248.19

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)C(=O)Nc1cc2[nH]ccc2cc1C(=O)O

Standard InChI:  InChI=1S/C11H8N2O5/c14-9(11(17)18)13-8-4-7-5(1-2-12-7)3-6(8)10(15)16/h1-4,12H,(H,13,14)(H,15,16)(H,17,18)

Standard InChI Key:  AHWMERGBWWROMM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 248.19

Molecular Weight (Monoisotopic): 248.0433

AlogP: 0.89

#Rotatable Bonds: 2

Polar Surface Area: 119.49

Molecular Species: ACID

HBA: 3

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.41

CX Basic pKa:

CX LogP: 1.58

CX LogD: -5.18

Aromatic Rings: 2

Heavy Atoms: 18

QED Weighted: 0.59

Np Likeness Score: -0.61

References

1. Andersen HS, Olsen OH, Iversen LF, Sørensen AL, Mortensen SB, Christensen MS, Branner S, Hansen TK, Lau JF, Jeppesen L, Moran EJ, Su J, Bakir F, Judge L, Shahbaz M, Collins T, Vo T, Newman MJ, Ripka WC, Møller NP..  (2002)  Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B.,  45  (20): [PMID:12238924] [10.1021/jm0209026]

2. Zhou M, Ji M..  (2005)  Molecular docking and 3D-QSAR on 2-(oxalylamino) benzoic acid and its analogues as protein tyrosine phosphatase 1B inhibitors.,  15  (24): [PMID:16230012] [10.1016/j.bmcl.2005.08.078]

3. Vidović D, Schürer SC..  (2009)  Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.,  52  (21): [PMID:19810703] [10.1021/jm9008899]

4. Cheng Y, Zhou M, Tung CH, Ji M, Zhang F..  (2010)  Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues.,  20  (11): [PMID:20452766] [10.1016/j.bmcl.2010.04.033]

5. Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A..  (2020)  Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.,  207  [PMID:32871344] [10.1016/j.ejmech.2020.112742]

Source

Source(1):

• Scientific Literature